Literature DB >> 29387634

Effects of endurance exercise and doxorubicin on skeletal muscle myogenic regulatory factor expression.

Colin J Quinn1,2, David S Hydock2,3.   

Abstract

BACKGROUND: The skeletal muscle toxicity that accompanies the chemotherapy drug doxorubicin (DOX) may lead to cancer patient weakness and fatigue. This myotoxicity involves myogenic regulatory factor (MRF) disruption which alters muscle integrity and regeneration. Endurance exercise enhances MRF expression and thereby may mitigate DOX-induced MRF disruptions. This study examined the effects of endurance training and DOX treatment on myogenic regulatory factor (MRF) expression.
METHODS: Male rats were exercise trained (EXER) or remained sedentary (SED) for two weeks. EXER and SED then received either DOX (15 mg/kg) or saline (SAL). Soleus, extensor digitorum longus (EDL), and diaphragm were excised 24 hours post injection, and MRF expression was analyzed.
RESULTS: Significant Myf5 drug and activity effects were observed in the soleus with EXER+DOX expressing higher Myf5 than SED+DOX. A significant drug effect was detected in soleus MyoD, and a significant activity effect was detected in soleus Mrf4. No main effects or interactions were observed in the EDL, but in the diaphragm, a significant activity effect was observed for Myf5 with EXER+DOX expressing higher levels than SED+DOX.
CONCLUSION: Doxorubicin treatment increased soleus MRFs and exercise boosted MRF response in soleus and diaphragm suggesting that exercise may enhance regenerative signaling with DOX treatment. LEVEL OF EVIDENCE: I b, individual randomized controlled trial.

Entities:  

Keywords:  anthracycline; diaphragm; fast muscle; slow muscle

Year:  2018        PMID: 29387634      PMCID: PMC5774914          DOI: 10.11138/mltj/2017.7.3.418

Source DB:  PubMed          Journal:  Muscles Ligaments Tendons J        ISSN: 2240-4554


  36 in total

1.  Muscle satellite cells are primed for myogenesis but maintain quiescence with sequestration of Myf5 mRNA targeted by microRNA-31 in mRNP granules.

Authors:  Colin G Crist; Didier Montarras; Margaret Buckingham
Journal:  Cell Stem Cell       Date:  2012-07-06       Impact factor: 24.633

2.  Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy.

Authors:  Mark Belham; Anton Kruger; Sophie Mepham; Giorgio Faganello; Colin Pritchard
Journal:  Eur J Heart Fail       Date:  2006-10-24       Impact factor: 15.534

3.  Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes.

Authors:  S M DeAtley; M Y Aksenov; M V Aksenova; B Harris; R Hadley; P Cole Harper; J M Carney; D A Butterfield
Journal:  Cancer Lett       Date:  1999-02-08       Impact factor: 8.679

4.  Mechanism of anthraquinone-induced calcium release from skeletal muscle sarcoplasmic reticulum.

Authors:  J J Abramson; E Buck; G Salama; J E Casida; I N Pessah
Journal:  J Biol Chem       Date:  1988-12-15       Impact factor: 5.157

5.  Effects of Exercise on Doxorubicin-Induced Skeletal Muscle Dysfunction.

Authors:  Eric C Bredahl; Keith B Pfannenstiel; Colin J Quinn; Reid Hayward; David S Hydock
Journal:  Med Sci Sports Exerc       Date:  2016-08       Impact factor: 5.411

6.  Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle.

Authors:  Ashley J Smuder; Andreas N Kavazis; Kisuk Min; Scott K Powers
Journal:  J Appl Physiol (1985)       Date:  2011-02-10

7.  Acylated and unacylated ghrelin inhibit doxorubicin-induced apoptosis in skeletal muscle.

Authors:  A P Yu; X M Pei; T K Sin; S P Yip; B Y Yung; L W Chan; C S Wong; P M Siu
Journal:  Acta Physiol (Oxf)       Date:  2014-04-02       Impact factor: 6.311

8.  Differential contractile impairment of fast- and slow-twitch skeletal muscles in a rat model of doxorubicin-induced congestive heart failure.

Authors:  Mert Ertunc; Yildirim Sara; Petek Korkusuz; Rustu Onur
Journal:  Pharmacology       Date:  2009-09-24       Impact factor: 2.547

9.  A role for the myogenic determination gene Myf5 in adult regenerative myogenesis.

Authors:  Barbara Gayraud-Morel; Fabrice Chrétien; Patricia Flamant; Danielle Gomès; Peter S Zammit; Shahragim Tajbakhsh
Journal:  Dev Biol       Date:  2007-09-11       Impact factor: 3.582

10.  Antineoplastic agent doxorubicin inhibits myogenic differentiation of C2 myoblasts.

Authors:  M Kurabayashi; R Jeyaseelan; L Kedes
Journal:  J Biol Chem       Date:  1993-03-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.